Autolus Therapeutics plc AUTL
Updated: 10 Aug 2026
No signal published yet
We already track Autolus Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Autolus Therapeutics plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Autolus Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 3, 2026, Autolus announced preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and raised its full-year 2026 revenue guidance to between $140 million and $150 million. The company also entered into a senior credit facility of up to $250 million with Perceptive Advisors, funded with an initial $75 million at closing. Full Q2 2026 financial results are scheduled for release on August 11, 2026.
What Firelda Watch includes for Autolus Therapeutics plc
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Autolus Therapeutics plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Autolus Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more